Louqian Zhang

Dr. Louqian Zhang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Neoplasia
Verified
Journal Article
Open access
YBYongkang Bai
Yongkang Bai
XLXiang Liu
Xiang Liu
LZLimin Zheng
Limin Zheng
SWSong Wang
Song Wang
JZJunli Zhang
Junli Zhang
LZLouqian Zhang
Louqian Zhang
Common sensitizing mutations in epidermal growth factor receptor (cEGFR), including exon 19 deletions (19-Del) and exon 21 L858R substitution, are associated with high sensitivity to EGFR-TKIs in NSCLC patients. The treatment for NSCLC patients with uncommon EGFR (uEGFR) mutations remains a subject of debate due to heterogeneity in treatment responses. In this manuscript, the targeted next-generation sequencing (NGS) data of a large cohort of EGFR-mutated NSCLC patients was assessed to elucidate genomic profiles of tumors carrying cEGFR or uEGFR mutations. The results showed that NSCLC patients with uEGFR mutations were more likely to harbor co-occurring genetic alterations in the Hippo pathway and a higher TMB compared with cEGFR-positive patients. Smoking-related mutations were found to significantly enriched in uEGFR-positive patients. Subgroup analyses were performed to identify potential prognostic biomarkers in patients harboring various EGFR subtype mutations. L858R-positive patients with co-existing ARID2 mutations had shorter progression-free survival (PFS) than those who were L858R- or 19-Del-positive but ARID2-negative (median: 2.3 vs. 12.0 vs. 8.0 months, P = 0.038). Furthermore, mutational profiles, such as top frequently mutated genes and mutational signatures of patients with various EGFR subtype mutations were significantly different. Our study analyzed the mutational landscape of NSCLC patients harboring cEGFR and uEGFR mutations, revealing specific genomic characteristics associated with uEGFR mutations that might explain the poor prognosis of first-generation EGFR-TKIs.

29 April 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
LWLei Wang
Lei Wang
SGShanchun Ge
Shanchun Ge
YZYe Zhang
Ye Zhang
DFDeqin Feng
Deqin Feng
TZTing Zhu
Ting Zhu
CZChaofeng Zhang
Chaofeng Zhang
The pathogenesis of pulmonary fibrosis (PF) is complex. It is characterized by myofibroblast hyperplasia and deposition of collagen protein. Indoleamine 2,3-dioxygenase 1 (IDO1) is expressed in lung fibroblasts and epithelial cells, but its functions in lung homeostasis and diseases remain elusive. Here, we characterize the critical role of IDO1 in PF patients and bleomycin (BLM)-induced PF mouse models. We find that IDO1 is significantly upregulated in the fibrotic lungs of patients and mice, showing a positive correlation with genes characteristic of fibrosis. Functionally, IDO1 knockout inhibits lung fibroblast proliferation, differentiation, mitochondrial biogenesis, and mitochondrial oxidative phosphorylation. Conversely, IDO1 overexpression and accumulation of kynurenine (Kyn) exacerbate progressive lung fibrosis. Mechanistically, IDO1-deletion activated profound mitochondrial fusion-enhanced potentially the capacity for fatty acid oxidation, along with activation of de novo glycolytic serine/glycine synthesis pathways and mitochondrial one-carbon metabolism. Wedelolactone (WEL), a small molecule IKK inhibitor, is found to strongly bind to IDO1 and effectively protect mice from PF in an IDO1-dependent manner. Collectively, this study characterizes a promotor role for IDO1 in PF and suggests a potential avenue of targeting IDO1 to treat lung diseases.

5 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LZLouqian Zhang
Louqian Zhang
JZJian Nong Zhou
Jian Nong Zhou
JWJun Wang
Jun Wang
GLGuo Dong Liang
Guo Dong Liang
JLJing Ying Li
Jing Ying Li
YSYun Tao Su
Yun Tao Su
N-Acetyltransferase (NAT) 2 is an important enzyme involved in the metabolism of different xenobiotics, including potential carcinogens, whose phenotypes were reported to be related to individual susceptibility to colorectal cancer (CRC). However, the results remain conflicting. To assess the relationship between NAT2 phenotypes and CRC risk, we performed this meta-analysis. A comprehensive literature search was conducted to identify all case-control or cohort studies of NAT2 acetylator status on the susceptibility of CRC by searching of PubMed and EMBASE, up to May 20, 2011. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association. A total of over 40,000 subjects from 40 published literatures were identified by searching the databases. No significantly elevated CRC risk in individuals with NAT2 slow acetylators compared with fast acetylators was found when all studies pooled (OR = 0.95, 95% CI: 0.87–1.04, I2 = 52.6%). While three studies contributed to the source of heterogeneity were removed, there was still null result observed (OR = 0.96, 95% CI: 0.90–1.03, P = 0.17 for heterogeneity, I2 = 17.8%). In addition, we failed to detect any associations in the stratified analyses by race, sex, source of controls, smoking status, genotyping methods or tumor localization. No publication bias was observed in this study. This meta-analysis suggests that the NAT2 phenotypes may not be associated with colorectal cancer development.

1 January 2023
Verified
Journal Article
Closed access
YWYazhou Wen
Yazhou Wen
DYDongshan You
Dongshan You
YBYongkang Bai
Yongkang Bai
JCJing Cao
Jing Cao
LZLouqian Zhang
Louqian Zhang
XXXiaoyang Xia
Xiaoyang Xia

7 September 2023 in Life Sciences
Verified
Journal Article
Closed access
WLWeichao Lv
Weichao Lv
HMHongcai Mao
Hongcai Mao
YRYang Ruan
Yang Ruan
SLShuaiyu Li
Shuaiyu Li
KSKuniyoshi Shimizu
Kuniyoshi Shimizu
CZChaofeng Zhang
Chaofeng Zhang

4 December 2024 in Cancer Letters
Verified
Journal Article
Closed access
YMYuan Mao
Yuan Mao
YCYufeng Chen
Yufeng Chen
XYXiaohui Yang
Xiaohui Yang
YHYiting He
Yiting He
DCDaixun Cui
Daixun Cui
HYHao Yuan
Hao Yuan